ScreenFect®A-plus is a multipurpose transfection reagent for pDNA, siRNA and mRNA delivery, and for cotransfection into a broad range of cell lines including HEK, HeLa, Mef and primary cell lines. This reagent has enhanced transfection efficiency compared to ScreenFect®A.
ScreenFect®A-plus is serum compatible and free of animal derived components. It has relatively low cytotoxicity, allowing easy One-Step cell transfection of recently detached cells. This One-Step procedure reduces the duration of your experiment by one day. Once diluted, ScreenFect®A-plus can be used for a period of up to four days. A dilution buffer is included with the reagent.
Features
- Enhanced transfection efficiency using less reagent per transfection
- less than 100ng DNA needed
- Extremely low cytotoxity; seed and transfect cells on the same day
- Easy and fast optimization protocol
- Serum compatible; no need to change media
- Free of animal derived components
- Applicable in high throughput screenings
Applications
- pDNA, siRNA and mRNA delivery
- Cotransfection into cell lines
Sizes
- S-6001-2 - ScreenFect®A-plus Transfection Reagent, 0.2ml + Dilution Buffer, 10ml
- S-6001 - ScreenFect®A-plus Transfection Reagent, 1ml + Dilution Buffer, 50ml
Publications
- Fischer, S.; Wagner, A.; Kos, A.; Aschrafi, A.; Handrick, R.; Hannemann, J.; Otte, K. Breaking limitations of complex culture media: Functional non-viral miRNA delivery into pharmaceutical production cell lines. Journal of Biotechnology, 2013, 168, 589 - 600.
- Liu, X.; Kato, Y.; Kato, K.; Sugawara, M.; Ogasawara, S.; Tsujimoto, Y.; Naganumga, Y.; Yamakawa, M.; Tsuchiya, T.; Takagi, M. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Medicine, 2013, 2, 803 - 814.
- Enlund, E.; Fischer, S., Handrick , S., Otte, K.; Debatin, K.; Wabitsch, M.; Fischer-Posovszky, P. Establishment of Lipofection for Studying miRNA Function in Human Adipocytes. Plos, 2014, 9, 101371.
- Fischer, S.; Buck, T.; Wagner, A.; Ehrhart, C.; Giancaterino, J.; Mang, S.; Schad, M.; Mathias, S.; Aschrafi, A. Handrick, R.; Otte, K. A functional high-content miRNA screen identifies miR-30 family to boost recombinant protein production in CHO cells. Biotechnolgy Journal, 2014, 9, 1279 - 1292.
- Kim, J.; Lee, S.; Park, C.; Park, S.; Yin, J.; Kim, J.; Park, J.; Lee, J.; Kim, H.; Kim, S. Rab3a promotes brain tumor initiation and progression. Molecular Biology Reports, 2014, 41, 5903 - 5911.
- Hackl, M.; Jadhav, V.; Klnert, G.; Karbiener, M.; Scheideler, M.; Grillari, J.; Borth, N. Analysis of microRNA transcription and post-transcriptional processing by Dicer in the context of CHO cell proliferation. Journal of Biotechnology, 2014, 190, 76 - 84.
- Chen, Q.; Su, Y.; Wesslowski, J.; Hagemann, A.; Ramialision, M.; Wittbrodt, J.; Scholpp. S.; Davidson, G. Tyrosine phosphorylation of LRP6 by Src and Fer inhibits Wnt/β?catenin signalling. EMBO reports, 2014, 15, 1223 - 1330.
- Diefenbacher, M.; Reich, D.; Dahley, O.; Kemler, D.; Litfin, M.; Herrlich, P.; Kassel, O. The LIM Domain Protein nTRIP6 Recruits the Mediator Complex to AP-1-Regulated Promoters. Plos, 2014, 9, 101371.
- Shaikibrahim, Z.; Offermann, A.; Braun, M.; Menon, R.; Syring, I.; Nowak, M.; Halbach, R.; Vogel, W.; Ruiz, C.; Zellweger, T.; Rentsch, C.; Svensson, M.; Andren, O.; Bubendorf, L.; Biskup, S.; Duensing, S.; Kirfel, J.; Perner, S. MED12 overexpression is a frequent event in castration-resistant prostate cancer. Society for Endocrinology, 2014.21, 663 - 675.
MoBiTec - Molecular Biotechnology
